Stroke Drug Development Targeting DAPK1

It has been conclusively shown that DAPK1 can influence stroke pathology by interacting with multiple proteins, such as NR2B, p53, and Tau. By affecting the interaction of DAPK1 with these proteins, it can effectively regulate cell death, excitotoxicity, neural deformation, synaptic damage, and other processes during the stroke. Therefore, modulating the interaction of DAPK1 with proteins can modulate the stroke pathological process in multiple ways and is a potential avenue for the treatment of stroke. In view of this, Ace Therapeutics offers comprehensive services to screen for modulators that effectively act on the interaction process of DAPK1 with the interacting proteins.

Screening of Modulators of The Interaction Between DAPK1 And Interacting Proteins for Stroke

Given that DAPK1 interacts with many proteins to regulate stroke pathology, Ace Therapeutics provides comprehensive services to explore the specific mechanisms of DAPK1 interactions with interacting proteins in the pathology of stroke.

• Predict the interaction sites of DAPK1 and its interacting proteins and identify the binding sites of small molecule modulators.
• Based on the small molecule library, virtual screening of small molecule modulators is performed by molecular docking and molecular dynamics simulations, along with the prediction of the ability of small molecule regulators to regulate DAPK1 / interacting proteins.
• Molecular dynamics simulations, MM / GBSA, and other techniques are used to analyze the binding process of modulators to proteins.
• The interaction of candidate modulators with target proteins is analyzed by surface plasmon resonance techniques.
• Validation of the regulatory activity of the candidate modulators on DAPK1 / interacting proteins based on an experimental model.
• Validation of the therapeutic effects of the candidate modulators on stroke and screening of effective drug candidates based on stroke models.

Preclinical Evaluation of Drug Candidates for the Treatment of Stroke

After the initial validation of the obtained drug candidates, Ace Therapeutics conducted more in - depth study services of the obtained drug candidates in screening to elucidate their specific efficacy and mechanism of action in stroke treatment.

• We provide different in vitro and in vivo stroke models to evaluate the therapeutic efficacy of the drug candidates in stroke.
• Through immunoprecipitation, yeast two - hybrid, and other techniques, we assay the effect of drug candidates on the interaction of DAPK1 and its interacting proteins.
• We screen genes or proteins associated with the interaction of DAPK1 and its interacting proteins during a stroke by gene microarray and protein microarray techniques to further elucidate the mechanism of action of DAPK1 and its interacting protein interactions.
• For genes or proteins that are closely associated with DAPK1 and its interacting proteins during stroke pathology, we provide different qualitative, quantitative, and localization services to further explore the mechanisms by which drug candidates exert their pharmacological effects.

At the same time, we can tailor our research services exclusively to your research needs. If you would like to learn more about our services, please feel free to contact us.

1. Wang, S., et al., Dapk1 signaling pathways in stroke: From mechanisms to therapies. Mol Neurobiol, 2017. 54(6): p. 4716-4722.